# Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation

Source: https://onco.cc/trials/nct06243354/  
OnCo record `nct06243354` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Test product: HYP-2090PTSA in advanced solid tumours, run by Sichuan Huiyu Pharmaceutical Co., Ltd, now recruiting.

## Summary

Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation is a phase 1/2 interventional study registered as NCT06243354 by Sichuan Huiyu Pharmaceutical Co., Ltd, with 257 participants planned, started 2024-02-04 and due to reach its primary completion in 2026-12. Interventions recorded: Test product: HYP-2090PTSA.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06243354
- Phase: 1/2
- Setting: An Open-label, Multi-center, Multi-cohort, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HYP-2090PTSA in Patients With Advanced Solidt Tumors Harboring KRAS Mutation
- Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd
- Enrolled: 257

## Sources

- ClinicalTrials.gov NCT06243354: https://clinicaltrials.gov/study/NCT06243354

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06243354.json